Skip to main content
. 2022 Feb 14;5(2):e2148415. doi: 10.1001/jamanetworkopen.2021.48415

Table. SARS-CoV-2 Immunoreactivity of Plasma Samples From 100 Healthy Vaccinated Individualsa.

Serologic assay result No. of participants (%) P value (total positive vs negative)c
BNT162b2 (n = 24) ChAdOX1-S (n = 24) Gam-COVID-Vac (n = 24) BBIBP-CorV (n = 24) BBIBP-CorV + BNT162b2 (n = 4)b
ELISA
Spike
Negative 0 5 (20.83) 12 (50.00) 17 (70.83) 0 .0002 (BNT162b2 vs Gam-COVID-Vac), .0001 (BNT162b2 vs BBIBP-CorV), .03 (ChAdOX1-S vs Gam-COVID-Vac), and .0005 (ChAdOX1-S vs BBIBP-CorV)
Total positive 24 (100.00) 19 (79.17) 12 (50.00) 7 (29.17) 4 (100.00)
Weak positive 2 (8.33) 2 (8.33) 5 (20.83) 4 (16.67) 1 (25.00)
Positive 22 (91.67) 17 (70.83) 7 (29.17) 3 (12.50) 3 (75.00)
NCP
Negative 23 (95.83) 21 (87.50) 23 (95.83) 21 (87.50) 3 (75.00) NA
Total positive 1 (4.17) 3 (12.50) 1 (4.17) 3 (12.50) 1 (25.00)
Weak positive 1 (4.17) 2 (8.33) 0 0 0
Positive 0 1 (4.17) 1 (4.17) 3 (12.50) 1 (25.00)
Neutralizing antibody
Washington strain
Not detected 5 (20.83) 12 (50.00) 18 (75.00) 19 (79.17) 1 (25.00) .03 (BNT162b2 vs ChAdOX1-S), .0002 (BNT162b2 vs Gam-COVID-Vac), .00005 (BNT162b2 vs BBIBP-CorV), and .03 (ChAdOX1-S vs BBIBP-CorV)
Detected 19 (79.17) 12 (50.00) 6 (25.00) 5 (20.83) 3 (75.00)
≤1:40 14 (58.30) 4 (16.70) 4 (16.70) 2 (8.33) 2 (50.00)
>1:40 5 (20.83) 8 (33.30) 2 (8.33) 3 (12.50) 1 (25.00)
Delta variant
Not detected 17 (70.83) 15 (62.50) 22 (91.60) 21 (87.50) 3 (75.00) .016 (ChAdOX1-S vs Gam-COVID-Vac) and .045 (ChAdOX1-S vs BBIBP-CorV)
Detected 7 (29.17) 9 (37.50) 2 (8.33) 3 (12.50) 1 (25.00)
≤1:40 4 (16.67) 3 (12.50) 1 (4.20) 2 (8.33) 0
>1:40 3 (12.50) 6 (25.00) 1 (4.20) 1 (4.20) 1 (25.00)
a

Determined by the spike-immunoglobulin G enzyme-linked immunoassay (ELISA), nucleocapsid protein (NCP)-ELISA, and end point absolute viral neutralization assay against the SARS-CoV-2 Washington strain and the B.1.617.2 (Delta) variant. Participants had received 1 of 4 COVID-19 vaccines: ChAdOX1-S (Covishield; Oxford/AstraZeneca), Gam-COVID-Vac (Sputnik V; Russian Direct Investment Fund), BBIBP-CorV (Sinopharm), or BNT162b2 (Pfizer/BioNTech).

b

The BBIBP-CorV + BNT162b2 group was not included in the statistical analysis because of the small sample size.

c

P values were recorded for the NCP-ELISA. The χ2 test was used to determine significance (<.05). NA, not applicable.